Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Cardiol Rep. 2006 Sep;8(5):370-6.

Atrial fibrillation: choosing an antiarrhythmic drug.

Author information

  • 1Division of Cardiovascular Diseases, Main Line Health Heart Center, Lankenau Hospital, 100 Lancaster Avenue, MOB East, Suite 558, Wynnewood, PA 19096, USA. tjrudo@comcast.net

Abstract

Atrial fibrillation is the most common arrhythmia encountered in clinical practice. The associated hemodynamic changes can lead to symptoms of palpitations, fatigue, light-headedness, or dyspnea. Extensive research in the use of antiarrhythmic drugs has been performed both to facilitate the conversion of atrial fibrillation to sinus rhythm and to maintain normal sinus rhythm. The relative merits of a rhythm control versus rate control strategy are briefly discussed. Efficacy of the available agents for pharmacologic cardioversion is reviewed in detail. Important drugs for maintenance of sinus rhythm include amiodarone, flecainide, propafenone, sotalol, and dofetilide. Selection of the appropriate antiarrhythmic drug must be individualized to the clinical situation, with Class IC drugs being first-line agents in the absence of structural heart disease. Regardless of agent selected, appropriate monitoring for development of adverse effects is of utmost importance.

PMID:
16956453
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk